CORRECTION OF MORPHOFUNCTIONAL DISORDERS IN EXPERIMENTAL PREECLAMPSY BY COMBINED USE OF TRIMETAZIDINE AND PURIFIED MICRONIZED FLAVONOID FRACTION AS WELL AS THEIR COMBINATIONS WITH METHYLAMPSY

The aim of the experiment was to determine effectiveness combined use trimetazidine and a purified micronized flavonoid fraction, as well their combinations with methyldopa, in comparison monotherapy same drugs correction morphofunctional disorders arising conditions experimental preeclampsia. An integrated/multimethodology approach is most effective way treatment for Therefore, an urgent task modern pharmacology study new when used combinations, included standards treatment. Materials methods . carried out at Research Institute Pharmacology Living Systems Belgorod State National University. performed on 200 female Wistar rats, weighing 250–300 g, which ADMA-like model preeclampsia had been reproduced. To assess degree emerging morphological functional disorders, following parameters were involved: blood pressure, coefficient endothelial dysfunction, microcirculation placenta, proteinuria, fluid contents greater omentum, morphometric indicators placental tissues fetal height weight parameters. Results (Preductal® MB) 6 mg/kg fraction (Detralex®) 260 mg/kg, combination methyldopa (Dopegit®) 86 leads more pronounced decrease compared dysfunction by 2.22, 2.19 1.94 times, respectively, relation “untreated” animals. There increase indices placenta 2.35, 2.21 2.03 respectively. In addition, there improvement fetuses. Conclusion results showed studied monotherapy. This indicates prospects complex therapy need further research this direction.